Current report
Open the filing on sec.gov
BioXcel Therapeutics, Inc. (BTAI)
OTC: BTAI · Pharmaceutical Preparations · New Haven, CT · filing with the SEC since 2017
The companyfiscal 2025, as filed
Revenue$642,000-71.7%
Net income-$69.9M-17.3%
Earnings per share$-5.73+75.6%
Operating cash flow-$57.6M+20.0%
Cash$28.4M-4.8%
Debt$84.7M-17.4%
Shareholders’ equity-$95.5M-2.5%
Shares, diluted12.2M+381.6%
Return on equityn/a
The recordfrom its filings
Filings in 202659
Newest filingOct 30 · 8-K
Annual reportMar 27, 2026
Quarterly reportAug 13, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted19
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Revenue $742,000Net income -$70.9MCash from operations -$50.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.